U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli ... sold by Lilly as Mounjaro for diabetes and Zepbound ...

Meta c Mark Zuckerberg took the stand on Monday in a historic antitrust trial that could force the tech giant to break off ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Zepbound, which has the same active ingredient, tirzepatide, is the brand name for the U.S. weight loss version, with Mounjaro sold for diabetes there. Lilly offers 5 mg, 7.5 mg and 10 mg vials of ...

Eli Lilly and Company discovers ... and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.